Source: Mycenax Biotech

Mycenax Biotech (TWO: 4726), a pioneer in Taiwan for biopharmaceutical CDMO services, announced today that the board of directors has finalized plans for private placement.

This private placement focused on a few key investors, of which JCR Pharmaceuticals Co., Ltd., a distinguished Japanese biopharmaceutical company, has become the largest shareholder (20.48%), followed by CENTER Laboratories, Inc. (20.46%).

In this private placement, JCR Pharmaceuticals Co., Ltd. purchased 42,000,000 shares and CENTER Laboratories, Inc. purchased 8,000,000 shares with a price at 32.5 NTD per share. The private placement was expected to reach a total amount of 1,625,000,000 NTD (~54.3 million USD).

For full release please visit www.mycenax.com.tw